A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
Status:
Recruiting
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone
(KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling
multiple myeloma than the stand or care treatment, which is lenalidomide, bortexomib, and
dexamethasone (VRD).
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center University of Miami